<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04786470</url>
  </required_header>
  <id_info>
    <org_study_id>116618</org_study_id>
    <nct_id>NCT04786470</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane Catheter Following Kidney Transplantation</brief_title>
  <official_title>Transversus Abdominis Plane Catheter Following Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous Infusion of Local Anesthetic After Kidney Transplantation&#xD;
&#xD;
      This is a phase III, randomized, double-blinded, sham-controlled trial comparing the use of a&#xD;
      continuous infusion of local anesthetic via transversus abdominis plane (TAP) catheter to a&#xD;
      saline infusion (sham) via TAP catheter along with standard postoperative analgesia in&#xD;
      patients undergoing kidney transplantation. Patients will have a TAP catheter placed at the&#xD;
      time of kidney transplantation by the surgical team under direct vision. They are then&#xD;
      randomized to a continuous infusion of local anesthetic or saline for 48 hours&#xD;
      postoperatively. Both groups will receive a standard postoperative analgesic regimen&#xD;
      including a Patient Controlled Analgesic (PCA) pump and multimodal analgesics including&#xD;
      acetaminophen and gabapentin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral morphine equivalent (OME)</measure>
    <time_frame>48 hours post kidney transplantation</time_frame>
    <description>OME in mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale pain rating</measure>
    <time_frame>12, 24, and 48 hours post kidney transplantation</time_frame>
    <description>Series of 5 faces that depict discomfort levels ranging from severe pain (score 5) to no pain at all (score 1). The higher the score, the more pain a patient has.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life score</measure>
    <time_frame>48 hours post kidney transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return of bowel function postoperatively</measure>
    <time_frame>Duration of admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of local anesthetic systemic toxicity</measure>
    <time_frame>Duration of admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative adverse events (surgical)</measure>
    <time_frame>Duration of admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed graft function</measure>
    <time_frame>Duration of admission</time_frame>
    <description>Defined as the requirement for hemodialysis/peritoneal dialysis within the first 7 days after kidney transplantation for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine (mmol/L) at time of discharge</measure>
    <time_frame>Duration of admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Duration of admission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Local Anaesthetic Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Infusion</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine infusion via transversus abdominis plane catheter.</description>
    <arm_group_label>Local Anaesthetic Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline infusion via transversus abdominis plane catheter.</description>
    <arm_group_label>Saline Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male, female, non-binary gender, aged &gt;18 years.&#xD;
&#xD;
          4. Undergoing a kidney transplant (deceased or living donor) as treatment for stage 5&#xD;
             chronic kidney disease (Glomerular filtration rate &lt; 15ml/min) either on dialysis, or&#xD;
             approaching dialysis&#xD;
&#xD;
          5. No history of allergy to any local anesthetic.&#xD;
&#xD;
          6. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study&#xD;
             duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current use of opioid pain medications prior to kidney transplantation.&#xD;
&#xD;
          2. Known allergic reactions to components of any local anesthetic medication.&#xD;
&#xD;
          3. Prior local anesthetic systemic toxicity.&#xD;
&#xD;
          4. History of chronic pain undergoing current active treatment for the same.&#xD;
&#xD;
          5. Age &lt;18 years (this analgesic approach has not been established in this population).&#xD;
&#xD;
          6. Unable or unwilling to use IV PCA pump for any reason (manual dexterity, cognitive&#xD;
             impairment, patient choice etc.).&#xD;
&#xD;
          7. Multi-visceral transplantation.&#xD;
&#xD;
          8. Incision other than standard Gibson incision.&#xD;
&#xD;
          9. Unilateral or bilateral nephrectomy at time of kidney transplant.&#xD;
&#xD;
         10. Advanced liver disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew C Rasmussen, MD</last_name>
    <email>arasmuss@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ephraim Tang, MD</last_name>
    <email>ephraim.tang@lhsc.on.ca</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University, Canada</investigator_affiliation>
    <investigator_full_name>Andrew Rasmussen</investigator_full_name>
    <investigator_title>Kidney and Pancreas Transplantation Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

